60031-11-0Relevant academic research and scientific papers
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease
Shook, Brian C.,Rassnick, Stefanie,Osborne, Melville C.,Davis, Scott,Westover, Lori,Boulet, Jamie,Hall, Daniel,Rupert, Kenneth C.,Heintzelman, Geoffrey R.,Hansen, Kristin,Chakravarty, Devraj,Bullington, James L.,Russell, Ronald,Branum, Shawn,Wells, Kenneth M.,Damon, Sandra,Youells, Scott,Li, Xun,Beauchamp, Derek A.,Palmer, David,Reyes, Mayra,Demarest, Keith,Tang, Yuting,Rhodes, Kenneth,Jackson, Paul F.
, p. 8104 - 8115 (2010)
The in vivo characterization of a dual adenosine A2A/A 1 receptor antagonist in several animal models of Parkinson's disease is described. Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimizat
ARYLINDENOPYRIMIDINES FOR TREATING NEURODEGENERATIVE AND MOVEMENT DISORDERS WHILE MINIMIZING CARDIAC TOXICITY
-
Page/Page column 48, (2012/01/06)
This invention provides novel arylindenopyrimidines of the Formula (I), and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A1 and/or A2a receptors. This invention also provides therapeutic
ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING
-
Page/Page column 14-15, (2012/01/13)
This invention provides novel arylindenopyrimidines of the Formula (I), and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A1 and/or A2a receptors. This invention also provides therapeutic
